Title Category Credit Event datesort ascending Cost
Navigating a Changing Landscape in TNBC: Pharmacist-Focused Strategies in the Era of Immunotherapy
  • Oncology
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • Participation
10/20/2020 $0.00 Symposium attendees will gain insights into the molecular heterogeneity and diverse clinical features of TNBC, a condition which comprises 15-20% of all breast cancer cases, and has historically had limited treatment options, been associated with earlier age of onset, more aggressive disease course, and poorer prognosis.
Putting NSCLC to the Test: Oncology Nurse Perspectives in the Era of Precision Medicine
  • Oncology
  • ANCC
  • Participation
10/20/2020 $0.00 Attendees will gain an appreciation of the latest advances in non-small cell lung cancer (NSCLC), including the nurse’s role in comprehensive biomarker testing strategies and biomarker-driven treatment approaches. Expert faculty will reflect on the lung cancer tumor board, with emphasis on the appropriate selection of targeted therapy based on patient- and biomarker-specific factors in oncogenic driver mutations.
Precision Medicine in NSCLC: Real-World Applications of Testing & Treatment for the Managed Care Pharmacist
  • Oncology
10/20/2020 $0.00 The last decade has seen expanded use of biomarker testing in non-small cell lung cancer (NSCLC) and a growing field of targeted therapies that have transformed the treatment landscape of advanced disease. The pace of changes in the field makes it difficult to translate the latest trial data and guideline recommendations into real-world practice. Gaps in appropriate testing or treatment can dramatically diminish survival gains seen in major cancer centers.
Optimizing Outcomes in Iron Deficiency Anemia: Adaptive Approaches for the OB/GYN
  • AMA PRA Category 1 Credit™
  • Participation
10/17/2020 $0.00 Iron deficiency anemia is a far-reaching condition of immense clinical impact in women’s health, with implications ranging from the global, epidemiological scale, to individual OB/GYN practices, and most importantly, to individual patients. As such, this educational initiative is designed to address the myriad challenges of iron deficiency anemia (IDA) in women’s health using a dynamic, multifaceted approach targeted to OB/GYNs.
Putting NSCLC to the Test: Oncology Nurse Perspectives in the Era of Precision Medicine
  • Oncology
  • ANCC
  • Participation
10/13/2020 $0.00 Attendees will gain an appreciation of the latest advances in non-small cell lung cancer (NSCLC), including the nurse’s role in comprehensive biomarker testing strategies and biomarker-driven treatment approaches. Expert faculty will reflect on the lung cancer tumor board, with emphasis on the appropriate selection of targeted therapy based on patient- and biomarker-specific factors in oncogenic driver mutations.
Immune-Related Adverse Events with Cancer Immunotherapy: Case-Based Challenges for the Oncology Nurse
  • Oncology
  • ANCC
  • Participation
10/07/2020 $0.00 Early identification of irAEs and initiation of systemic immunosuppression can improve outcomes without compromising the efficacy of immune checkpoint inhibition. As front-line caregivers, oncology nurses are optimally positioned to quickly identify such adverse events and employ appropropriate management strategies.
Navigating the Evolving Paradigm in Heart Failure: The Emerging Impact of SGLT2 Inhibition
  • Cardiology
10/01/2020 $0.00 This educational initiative is targeted to physicians, nurses, nurse practitioners, pharmacists, scientists, and health care professionals who specialize or have an interest in heart failure. Designed to provide an exhaustive overview of new and emerging data as well as foster meaningful collaboration, this accredited activity will evaluate the pathophysiologic mechanisms linking type 2 diabetes (T2D) and heart failure (HF), and explore the early evolution of SGLT2 inhibition in the era of cardiovascular outcomes trials (CVOTs).
Traversing New Terrains In CLL: The Emerging Role Of BTK Inhibitors In The Treatment Landscape
  • Oncology
  • ANCC
  • Participation
09/29/2020 $0.00 The objective of this activity is to provide evidence-based information on the latest developments for the use of Bruton’s tyrosine kinase (BTK) inhibitors in patients with chronic lymphocytic leukemia (CLL). Given the demonstrated clinical benefit of BTKi therapy and its advantages over chemotherapy, it is essential for patients that the adoption of BTKi therapy continues to accelerate. Optimizing patient adherence to oral BTKis is vital to achieving efficacy and improving clinical outcomes.
Neurology Residents Scholar Program
  • Neurology
09/24/2020 $0.00 The NRSP is an epilepsy-focused educational opportunity for second- and third-year neurology residents. NRSP is an intensive multi-day course that addresses all clinical aspects of epilepsy, including the latest developments in diagnosis and treatment. Founded by the late Dr. John Gates of the Minnesota Epilepsy Group, PA, this is the NRSP’s eighteenth year educating residents about epilepsy to improve patient care.
Traversing New Terrains In CLL: The Emerging Role Of BTK Inhibitors In The Treatment Landscape
  • Oncology
  • ANCC
  • Participation
09/23/2020 $0.00 The objective of this activity is to provide evidence-based information on the latest developments for the use of Bruton’s tyrosine kinase (BTK) inhibitors in patients with chronic lymphocytic leukemia (CLL). Given the demonstrated clinical benefit of BTKi therapy and its advantages over chemotherapy, it is essential for patients that the adoption of BTKi therapy continues to accelerate. Optimizing patient adherence to oral BTKis is vital to achieving efficacy and improving clinical outcomes.

Pages